129Xe MRI Clinical Trials Consortium

Annual Meeting Information


Group Photo at the Annual Meeting in Miami FL 2020


The 129Xe MRI Clinical Trials Consortium (Xe MRI CTC) was established in 2015 and consists of 8 Clinical Research Centers with established129Xe in-vivo MRI capabilities and independent INDs (or equivalent) within North America and the United Kingdom.  These sites are in Cincinnati OH, Charlottesville VA, Durham NC, Hamilton, ON, London ON, Madison WI, Sheffield UK, and Toronto ON.

Purpose of the Consortium
The purpose of this cooperative research consortium is to facilitate clinical research, education, and awareness of the capabilities of 129Xe MRI through support for 1) collaborative clinical research in both adult and pediatric lung diseases, including longitudinal studies of individuals with lung disease, crossectional clinical studies, phase one, two, and three trials, and/or pilot and demonstration projects; 2) training of clinical investigators in hyperpolarized gas research; 3) providing a test bed for novel approaches and technologies for biomarkers and image guided interventions, and 4) offering a platform for sharing protocols, MRI sequences, and image analysis algorithms for the associated institutions.   Each of the individual Clinical Research Centers is comprised of basic and clinical investigators, institutions, CTSAs, and relevant organizations, for the utilization of hyperpolarized gases in translational research.
This cooperative program facilitates
     •  Identification of biomarkers for disease risk
     •  Mechanisms for monitoring disease severity/activity 
     •  Development of image guided interventions 
     •  Tracking responses to treatment
     •  Identification of clinical outcomes 
The Consortium encourages development of new approaches to diagnosis, prevention, and treatment of lung diseases via NIH- and industry-funded research.
Xe Consortium sites are located at the following institutions (alphabetized by location):

Cincinnati Children’s Hospital Medical Center (CCHMC) and the University of Cincinnati (UC), Cincinnati, Ohio, USA
•     Jason C Woods, PhD, Frank McCormack, MD, John P. Clancy, MD, Zackary Cleveland, PhD, Bruce Trapnell MD, Theresa Guilbert, MD
University of Virginia, Charlottesville, Virginia, USA
•     John Mugler, PhD, Y. Michael Shim, MD, Jaime Mata, PhD, Borna Mehrad, MD, W. Gerald Teague, MD
University of Missouri, Columbia Missouri, USA
•     Talissa Altes, MD, Robert Thomen, PhD
Duke University Medical Center, Durham, North Carolina, USA
•     Bastiaan Driehuys, PhD, Loretta Que, MD, Tony Huang, MD
Robarts Research Institute and Western University, London, Ontario, Canada
•     Grace Parraga, PhD, David McCormack, MD
McMaster University, Hamilton, Ontario, Canada
•     Sarah Svenningsen, PhD
University of Wisconsin, Madison Wisconsin, USA
•     Sean Fain, PhD, Scott Nagle, MD, PhD, Ron Sorkness, PhD, Loren Denlinger, MD, PhD, Michael Rock, MD
University of Sheffield, Sheffield, United Kingdom
•     Jim Wild, PhD, David Kiely, MD
SickKids Hospital and University of Toronto, Toronto, Ontario, Canada
•     Giles Santyr, PhD, Felix Ratjen, MD, Padmaja Subbarao MD
University of Kansas Medical Center​
•     Mario Castro, MD, Chase Hall, MD, Peter Niedbalski, PhD
British Columbia Children’s Hospital and University of British Columbia
•     Don Sin, MD, Jonathan Rayment, MD, Rachel Eddy, PhD